| Pharmaceutical Information |
| Drug Name |
Lofexidine |
| Drug ID |
BADD_D02564 |
| Description |
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine.[T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.[T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] |
| Indications and Usage |
Lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment. It is the first non-opioid medication for the symptomatic management of opioid discontinuation.[L2801]
Opioid withdrawal syndrome is a debilitating manifestation of opioid dependence.[A33085] This condition is extremely unpleasant lasting several days with some of the main features being abdominal pain, nausea, diarrhea, mydriasis, lacrimation, and piloerection. These symptoms are often observed after abrupt reductions in the opioid dose and can be resolved by re-administration of the opioid.[A33088] |
| Marketing Status |
approved; investigational |
| ATC Code |
N07BC04 |
| DrugBank ID |
DB04948
|
| KEGG ID |
D04765; D08141
|
| MeSH ID |
C025655
|
| PubChem ID |
30668
|
| TTD Drug ID |
D0K0MW
|
| NDC Product Code |
11014-0309 |
| UNII |
UI82K0T627
|
| Synonyms |
lofexidine | 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline | lofexidine hydrochloride | lofexidine monohydrochloride | Lofexidine mono-hydrochloride | Lucemyra | BritLofex | lofexidine, (+-)-isomer |
|
| Chemical Information |
| Molecular Formula |
C11H12Cl2N2O |
| CAS Registry Number |
31036-80-3 |
| SMILES |
CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
